neoplastic meningitis

Also found in: Wikipedia.

ne·o·plas·tic men·in·gi·tis

infiltration of subarachnoid space by neoplastic cells, typically medulloblastoma or metastatic carcinoma.
Mentioned in ?
References in periodicals archive ?
Neoplastic meningitis is also referred to as lymphomatous meningitis in patients with lymphoma.
Patients with neoplastic meningitis usually have accompanying headache, meningeal signs, and evidence of increased ICP.
Grossman SA, moynihan TJ (1991) Neoplastic meningitis.
Diagnosis and individualized therapy of neoplastic meningitis.
Their topics include the pathology and molecular genetics of common brain tumors, malignant gliomas in adults, low grade astrocytomas, pediatric neuro-oncology, the managing intramedullary spinal cord tumors, medical complications in the management of brain tumor, brain metastases, neoplastic meningitis, the neurotoxicity of chemotherapy, paraneoplastic disorders, and neurological complications of bone marrow and organ transplantation.
Its two marketable products are DepoCyt for treating cancer-related neoplastic meningitis and DepoDur for the treatment of post-operative pain.
The full approval was based on findings from two randomized controlled clinical trials that included over 200 patients with neoplastic meningitis related to solid tumors, lymphoma or leukemia.
Approximately 25,000 cases of neoplastic meningitis occur annually, of which approximately 40 percent are lymphomatous meningitis and 60 percent are neoplastic meningitis in patients with solid tumors.
Neoplastic meningitis occurs when metastases from lymphomas, solid tumors, or leukemia spread to the tissue surrounding the brain and spinal cord.
Lymphomatous meningitis is a subtype of neoplastic meningitis (NM).
Food and Drug Administration (FDA) has advised the company that it is currently scheduling its New Drug Application (NDA) for DepoCyt(TM) for the treatment of neoplastic meningitis (NM) from lymphomas for review by the FDA's Oncologic Drugs Advisory Committee (the "Committee") on Nov.
Food and Drug Administration (FDA) inviting the company to submit a New Drug Application (NDA) for DepoCyt(tm), an anti-cancer drug for the treatment of neoplastic meningitis (NM) from lymphomas.